



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Audited Financial Results for the Quarter/year ended 31.03.2011

Particulars	(Rs. in lacs)			
	Quarter ended 31.03.2011 Audited	Quarter ended 31.03.2010 Audited	12 Months ended 31.03.2011 Audited	12 Months ended 31.03.2010 Audited
1(a) Net sales/Income from Operations	3185.53	3957.76	16095.50	13959.34
1(b) Other Operating Income				
Total	3185.53	3957.76	16095.50	13959.34
2 Expenditure				
a. (Inc./Dec. in Stock in trade and work in progress)	-643.34	-231.38	192.46	-1042.09
b. Consumption of Raw Materials	2227.48	2430.44	7379.61	7219.40
c. Purchase of traded goods	25.06	20.01	727.95	1372.92
d. Employees Cost	749.91	604.09	3222.48	2378.78
e. Depreciation	53.64	58.62	220.09	208.50
f. Other Expenditure	672.01	627.02	3119.94	2458.50
g. Total	3084.76	3508.80	14862.53	12596.01
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	100.77	448.96	1232.97	1363.33
4 Other Income	26.02	36.30	26.02	36.30
5 Profit before Int. & Exceptional Items (3+4)	126.79	485.26	1258.99	1399.63
6 Interest	50.72	93.88	332.18	349.62
7 Profit After Interest but before Exceptional items (5 - 6)	76.07	391.38	926.81	1050.01
8 Exceptional Items				
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8)	76.07	391.38	926.81	1050.01
10 Tax expense	36.85	25.81	208.85	125.81
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	39.22	365.57	717.96	924.20
12 Extraordinary Items (net of tax expense)				
13 Net Profit (+) Loss (-) for the period (11-12)	39.22	365.57	717.96	924.20
14 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr.			6615.03	6049.30
16 Earnings Per Share (EPS)				
a. Basic & diluted EPS before extraordinary items for the period.	0.15	1.40	2.74	3.53
b. Basic & diluted EPS after extraordinary items for the period.	0.15	1.40	2.74	3.53
17 Public shareholding :				
- Number of shares	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding				
a. Pledged / Encumbered				
- Number of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
b. Non - encumbered				
- Number of shares	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%

Notes

1. The Audited Financial Results for the Quarter ended 31.3.2011 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 12-8-2011
2. No complaints were pending at the beginning/end of the quarter ended 31.3.2011. However 45 requests for change of address/ dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
3. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
4. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
5. Previous Year Figures have been regrouped / rearranged where ever necessary.
6. The Board has recommended a dividend of Rs. 0.50 per equity shares on 2,61,98,000 Equity shares of Rs. 5/- each for the year 2010-11



Place : New Delhi
Date : 12.08.2011

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director